Algorae Pharmaceuticals (ASX:1AI) Debt-to-Equity: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Algorae Pharmaceuticals Debt-to-Equity?

Algorae Pharmaceuticals ASX:1AI Debt-to-Equity is 0.00 as of Dec. 2025. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, Algorae Pharmaceuticals ranks worse than 103519.57% on this metric.

Algorae Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Algorae Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was A$0.00 Mil. Algorae Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$1.89 Mil. Algorae Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Algorae Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Algorae Pharmaceuticals was 0.10. The lowest was 0.00. And the median was 0.08.

ASX:1AI's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Algorae Pharmaceuticals  (ASX:1AI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Algorae Pharmaceuticals Debt-to-Equity Related Terms

Algorae Pharmaceuticals Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Algorae Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Algorae Pharmaceuticals Debt-to-Equity Chart

Algorae Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Algorae Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:1AI vs VRTX, REGN, ALNY: Debt-to-Equity Comparison

For the Biotechnology subindustry, Algorae Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algorae Pharmaceuticals Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Debt-to-Equity falls into.


Algorae Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Algorae Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 2.229
=0.00

Algorae Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.89
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Algorae Pharmaceuticals (ASX:1AI) has a Debt-to-Equity of 0.00 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Algorae Pharmaceuticals and its competitors. According to the industry distribution chart, Algorae Pharmaceuticals ranks #999999 out of 966 companies in the Biotechnology industry.
Is Algorae Pharmaceuticals' Debt-to-Equity too high?
Algorae Pharmaceuticals' current Debt-to-Equity is 0.00. Based on the distribution chart, Algorae Pharmaceuticals ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Algorae Pharmaceuticals' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #999999 out of 966 companies for Debt-to-Equity. This places Algorae Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Algorae Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Debt-to-Equity is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Algorae Pharmaceuticals Business Description

Other Exchanges LVCLF:USALHI0:Germany
Address 525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.